ANAC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANAC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Anacor Pharmaceuticals's Enterprise Value is $445.50 Mil. Anacor Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 was $-60.73 Mil. Therefore, Anacor Pharmaceuticals's EV-to-EBIT ratio for today is -7.34.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Anacor Pharmaceuticals's Enterprise Value is $445.50 Mil. Anacor Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 was $-60.05 Mil. Therefore, Anacor Pharmaceuticals's EV-to-EBITDA ratio for today is -7.42.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Anacor Pharmaceuticals's Enterprise Value is $445.50 Mil. Anacor Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2016 was $84.63 Mil. Therefore, Anacor Pharmaceuticals's EV-to-Revenue ratio for today is 5.26.
The historical data trend for Anacor Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anacor Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 141.43 | 165.22 | 573.33 | 1,305.63 | 4,976.67 |
Anacor Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | |
Enterprise Value | Get a 7-Day Free Trial | 2,397.93 | 3,302.89 | 5,105.97 | 4,976.67 | 2,351.35 |
For the Biotechnology subindustry, Anacor Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Anacor Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Anacor Pharmaceuticals's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Anacor Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2015 is calculated as
Enterprise Value (A: Dec. 2015 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 5057.757276 | + | 0 | + | 61.276 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0 | + | 0 | - | 142.361 |
= | 4,976.67 |
Anacor Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2016 is calculated as
Enterprise Value (Q: Mar. 2016 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 2424.860805 | + | 0 | + | 62.255 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0 | + | 0 | - | 135.766 |
= | 2,351.35 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anacor Pharmaceuticals (NAS:ANAC) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Anacor Pharmaceuticals's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 445.500 | / | -60.725 | |
= | -7.34 |
Anacor Pharmaceuticals's current Enterprise Value is $445.50 Mil.
Anacor Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.73 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Anacor Pharmaceuticals's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 445.500 | / | -60.051 | |
= | -7.42 |
Anacor Pharmaceuticals's current Enterprise Value is $445.50 Mil.
Anacor Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.05 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Anacor Pharmaceuticals's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 445.500 | / | 84.626 | |
= | 5.26 |
Anacor Pharmaceuticals's current Enterprise Value is $445.50 Mil.
Anacor Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $84.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Anacor Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Keith R Leonard | director | ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
William Jl Rieflin | director | NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Anders D Hove | director | 30 ROCKEFELLER PLAZA, SUITE 5508, NEW YORK NY 10112 |
Lucy Shapiro | director | 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121 |
Graeme Bell | officer: Executive VP and CFO | 1324 WAVERLY ROAD, GLADWYNE PA 19035 |
Ryan T Sullivan | officer: EVP and General Counsel | C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07855 |
Wendall Wierenga | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Paul L Berns | director, officer: President and CEO | 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020 |
Mark Leschly | director | RHO CAPITAL PARTNERS, INC., 152 W 57TH ST 23RD FL, NEW YORK NY 10019 |
Geoffrey M. Parker | officer: Executive Vice President & CFO | 15 RIORDAN PLACE, MENLO PARK CA 94025 |
Paul H Klingenstein | director | 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301 |
David P Perry | director, officer: President and CEO | 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
Rho Management Ventures Iv Llc | 10 percent owner | 124 DUNE RD, QUOGUE NY 11959 |
Rho Ventures Iv Qp Lp | 10 percent owner | 124 DUNE RD, QUOGUE NY 11959 |
Rho Ventures Iv Lp | 10 percent owner | 124 DUNE ROAD, QUOGUE NY 11959 |
From GuruFocus
By Business Wire Business Wire • 02-10-2023
By Business Wire Business Wire • 06-02-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.